GlaxoSmithKline announced that the United States Food and Drug Administration (FDA) has granted Priority Review for Promacta®/Revolade® (eltrombopag) for the short-term treatment of patients with chr
read more » Discuss Add this link to...Bury Add to:
| Bookmarks